Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Our e-services for applications, projects and assessments (the eServices portal) close on Thursday 26 January at 4:30pm because of system upgrades. We expect to open them again on Friday 27 January at 8am the latest.

Toward the prevention and treatment of cerebral palsy through genetic and epigenetic modulation

Reference number
Coordinator Göteborgs Universitet
Funding from Vinnova SEK 2 918 182
Project duration January 2016 - September 2019
Status Completed

Purpose and goal

The main purpose of this project is to identify CP-related genes and biomarkers and to develop methods for early screening of high-risk infants and early intervention to reduce the incidence of CP. We have identified CP-causative genes through whole-exosome sequencing and biomarkers through multi-omics analysis. This first-stage work has reached goal of the project, and further functional tests and validation are ongoing through collaborative work.

Expected results and effects

This project has achieved progress by 1) promoting the career development for the project leader, 2) identifying new genes for CP, and 3) establishing new international collaborations. The results of the project will promote academic development in the field of perinatal brain injury and CP in Gothenburg and in Sweden, and further application of the results will reduce the incidence of CP, which represents a large burden on the individuals, their families, and society.

Planned approach and implementation

This research seeks to identify causative genes or biomarkers of perinatal brain injury and CP in order to develop methods for early screening of high-risk infants and for preventing or reducing the incidence of CP. The collaboration promotes not only high-quality scientific research, but also the translation from basic research to clinically useful techniques that will ultimately benefit patients who otherwise might suffer from life-long handicaps.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 8 January 2019

Reference number 2015-04780

Page statistics